Earnings Call · Q1 FY2023·2023-05-08

Q1 23EPS +10.42%·Rev n/aQ4 22EPS +8.89%·Rev n/aQ3 22EPS +77.27%·Rev n/aQ2 22EPS +22.45%·Rev n/a⚠ consensus missing

Atea Pharmaceuticals, Inc. AVIR

Jonae Barnes — Investor Relations or Communications

Jean-Pierre Sommadossi — Chief Executive Officer

Janet Hammond — Chief Medical Officer or Head of Clinical Development

Andrea Corcoran — Chief Financial Officer

−2.6%1d on move date−2.2% vs SPY3d−2.6%5d+1.5%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVIR calls or request research access.

More AVIR calls Browse calls Request research access